noom compounded semaglutide Unboxing GLP-1ᴿˣ Microdosing GLP-1 for Weight Loss

The goal was to build the muscle memory (pun intended) of reaching for protein early in the day

23.7% - the highest delta which I have seen so far (I added a table with a few other examples of delta between efficacy and treatment regimen estimands, which apparently correlates with drop-out rates)

Formulated with 15% ethel ascorbic acid, a stabilized form of vitamin C, it also includes probiotics, which studies show support skin health by protecting the skin microbiome and boosting skins immune response

Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

Semaglutide reduces cardiovascular event risk as shown in the SELECT trial